Printer Friendly

WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR LOPERAMIDE HYDROCHLORIDE ORAL SOLUTION

 CORONA, Calif., June 3 /PRNewswire/ -- Watson Pharmaceuticals Inc. (NASDAQ: WATS) today announced that its wholly owned subsidiary, Watson Laboratories Inc., has received approval from the Food and Drug Administration (FDA) for an oral solution of Loperamide Hydrochloride 1mg/5ml. Loperamide Hydrochloride is used in the treatment of diarrhea.
 According to Dr. Allen Chao, president and chief executive officer, Loperamide oral solution will be competitive with Imodium AD(R) and Pepto Diarrhea Control(R), in a market which is estimated at $25 million. The company expects to begin shipping the product by the end of the third quarter 1993. "The company is optimistic that the product will contribute positively to earnings," noted Chao.
 Watson Pharmaceuticals manufactures and distributes off-patent pharmaceuticals and is developing advanced drug delivery systems designed to enhance the therapeutic benefits of pharmaceutical compounds.
 -0- 6/3/93
 /CONTACT: Doug Sherk or Ken Dennard, 415-296-7383, or June Filingeri or Miriam Adler, 212-850-5600, all of Morgen-Walke, for Watson Pharmaceuticals/
 (WATS)


CO: Watson Pharmaceuticals Inc.; Watson Laboratories Inc. ST: California IN: MTC SU:

GT-SG -- SF004 -- 4707 06/03/93 06:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:181
Previous Article:INTERNATIONAL TOTALIZATOR SYSTEMS RECEIVES U.S. $600,000 ADD-ON ORDER FROM NEW SOUTH WALES LOTTERY
Next Article:TELECOMMUNICATIONS GAMING SIMULATOR VIRTUAL REALITY JOINT-MARKETING ANNOUNCED AT CES BY INTERACTIVE TECHNOLOGY MAJORS
Topics:


Related Articles
PERRIGO RECEIVES FDA APPROVAL TO MARKET LOPERAMIDE HYDROCHLORIDE LIQUID
PERRIGO RECEIVES FDA APPROVAL TO MARKET LOPERAMIDE HYDROCHLORIDE LIQUID
PERRIGO RECEIVES FDA APPROVAL TO MARKET LOPERAMIDE HYDROCHLORIDE CAPLET
WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR VERAPIMIL HYDROCHLORIDE TABLET
WATSON PHARMACEUTICALS ANNOUNCES RECORD SECOND QUARTER AND SIX-MONTH RESULTS
A.L. LABORATORIES ANNOUNCES FDA APPROVAL FOR LOPERAMIDE CAPLETS
WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR GUANFACINE-HYDROCHLORIDE TABLET
WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL TO MARKET ACEBUTOLOL HYDROCHLORIDE CAPSULES
Somerset Initiates Legal Action Against FDA
Watson Pharmaceuticals Acquires Exclusive Rights to Dilacor XR(R) From Rhone-Poulenc Rorer

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters